Abstract: The invention provides an exonuclease or an enzymatically active fragment thereof, said exonuclease having the amino acid sequence of SEQ ID NO:1 or an amino acid sequence which is at least about 50% identical thereto, wherein said exonuclease or enzymatically active fragment thereof (i) is substantially irreversibly inactivated by heating at a temperature of about 55° C. for 10 minutes in a buffer consisting of 10 mM Tris-HCl, pH 8.5 at 25° C., 50 mM KCl and 5 mM MgCl2; (ii) is substantially specific for single stranded DNA; and (iii) has a 3?-5? exonuclease activity. The invention further provides a method of removing single stranded DNA from a sample, a method of nucleic acid amplification, a method of reverse transcription and a method of nucleic acid sequence analysis in which the exonuclease or enzymatically active fragment thereof is used.
Type:
Grant
Filed:
August 13, 2019
Date of Patent:
September 29, 2020
Assignees:
ARCTICZYMES AS, UNIVERSITETET I TROMSø—NORGES ARKTISKE UNIVERSITET
Inventors:
Terese Solstad, Elisabeth Lill Andreassen, Marit Sjo Lorentzen, Olav Lanes, Morten Elde, Atle Noralf Larsen, Yvonne Piotrowski, Nils Peder Willassen
Abstract: This invention provides an amadoriase having high reactivity with ?-fructosyl hexapeptide (?F6P) derived from the ?-chain amino terminus of glycated hemoglobin (HbAlc), which enables satisfactory quantification of ?F6P cleaved from HbAlc. A novel amadoriase is derived from the amadoriase of the genus Coniochaeta by substitution of one or more amino acids at positions selected from the group consisting of positions 62, 63, 102, 106, 110, 113, 355, and 419. Such amadoriase enables rapid, simple, accurate, and satisfactory quantification of ?F6P cleaved from HbAlc. With the use of such amadoriase, a method for measurement of HbAlc by an enzymatic method and a kit for measurement of HbAlc that are based on the same principle as used in the conventional standard method and excellent in terms of the relevance with the standard method.
Abstract: Fungal glucoamylases from Aspergillus fumigatus—expressed in Trichoderma reesei host cells (AfGATR) are provided. Trichoderma reesei host cells express AfGATRs at higher, or at least comparable, levels to natively expressed AfGA Aspergillus fumigatus. AfGATRs, including AfGA1TR and AfGA2TR, exhibit high activity at elevated temperatures and at low pH, so AfGATRs can be used efficiently in a process of saccharification in the presence of alpha-amylase, such as Aspergillus kawachii alpha-amylase (AkAA). AfGATRs advantageously catalyze starch saccharification to an oligosaccharide composition significantly enriched in DP1 (i.e., glucose) compared to the products of saccharification catalyzed by Aspergillus niger glucoamylase (AnGA) or native AfGA expressed in Aspergillus fumigatus. AfGATRs such as AfGA1TR, AfGA2TR or a variant thereof can be used at a lower dosage than AnGA and natively expressed AfGAs to produce comparable levels of glucose.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
September 8, 2020
Assignee:
Danisco US INC
Inventors:
Jing Ge, Ling Hua, Sung Ho Lee, Jalsen Li, Jayarama K Shetty, Zhongmei Tang, Bo Zhang, Kun Zhong
Abstract: The present invention relates to variant thioesterases and their use in plants, e.g., to increase enzymatic activity and to promote increased production of mid-chain length fatty acids (e.g., 8 to 14 carbons) and at desired ratios. Further disclosed herein are methods of manufacturing renewable chemicals through the manufacture of novel triglyceride oils followed by chemical modification of the oils. Oils containing fatty acid chain lengths of C8, C10, C12 or C14 are also disclosed and are useful as feedstocks in the methods described herein.
Type:
Grant
Filed:
January 10, 2020
Date of Patent:
September 1, 2020
Assignee:
CORBION BIOTECH, INC.
Inventors:
David Davis, Scott Franklin, Jeffrey L. Moseley, Riyaz Bhat
Abstract: The present disclosure relates to recombinant hemoglobins with improved oxygen carrying capacity and methods of preparation and use thereof. The present disclosure also relates to a pharmaceutical composition including the recombinant hemoglobin useful for treating oxygen deficiency related diseases or conditions, such as stroke, hemorrhagic shock, peripheral arterial disease (PAD), acute mountain sickness (AMS), cancer, and Parkinson's disease (PD).
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
August 25, 2020
Assignee:
Cheer Global Limited
Inventors:
Sui Yi Kwok, Norman Fung Man Wai, Shan Yu, Terence Shau Yin Wai
Abstract: Recombinant DPO4-type DNA polymerase variants with amino acid substitutions that confer modified properties upon the polymerase for improved single molecule sequencing applications are provided. Such properties may include enhanced binding and incorporation of bulky nucleotide analog substrates into daughter strands and the like. Also provided are compositions comprising such DPO4 variants and nucleotide analogs, as well as nucleic acids which encode the polymerases with the aforementioned phenotypes.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
August 18, 2020
Assignee:
Stratos Genomics, Inc.
Inventors:
Mark Stamatios Kokoris, Marc Prindle, Melud Nabavi, Craig Ostrander, Taylor Lehmann, Samantha Vellucci, Michael Kovarik, Jack Chase, Robert Busam, Miranda Lahman
Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
August 18, 2020
Assignee:
SEATTLE CHILDREN'S HOSPITAL
Inventors:
Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda, David J. Rawlings
Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
Type:
Grant
Filed:
July 20, 2016
Date of Patent:
August 18, 2020
Assignee:
SEATTLE CHILDREN'S RESEARCH INSTITUTE
Inventors:
Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
Type:
Grant
Filed:
July 20, 2016
Date of Patent:
August 18, 2020
Assignee:
SEATTLE CHILDREN'S RESEARCH INSTITUTE
Inventors:
Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.
Type:
Grant
Filed:
January 4, 2018
Date of Patent:
August 18, 2020
Assignee:
Codexis, Inc.
Inventors:
Oscar Alvizo, David Elgart, Robert Kevin Orr, James Nicholas Riggins, Anna Fryszkowska, Katrina W. Lexa, Xiang Yi, Da Duan, Courtney Dianne Moffett, Nikki Dellas, Vesna Mitchell
Abstract: The invention concerns the use of the MCM7 gene to confer resistance to an organic acid, preferably acetic acid, to a yeast strain during glucose fermentation.
Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Grant
Filed:
March 4, 2020
Date of Patent:
July 28, 2020
Assignee:
NOVOZYMES A/S
Inventors:
Carsten Andersen, Signe E. Larsen, Esben Peter Friis, Pernille Ollendorff Micheelsen, Anders Viksoee-Nielsen, Randy Deinhammer, Xinyu Shen
Abstract: A novel protein deamidase having an activity of directly acting on a side chain amide group of an asparagine residue in a protein to form a side chain carboxyl group and release ammonia, a microorganism that produces the same, a gene encoding the same, a method for producing the same, and use of the same are provided. A bacterium classified into the class Actinobacteria is cultured to generate protein deamidase, and the enzyme is collected from culture.
Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
July 21, 2020
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
Abstract: The present invention provides L-amino acid ?-ligase represented by sequence number 1 (SEQ ID NO. 1), which is a mutant protein including substitution of at least 1-3 amino acid residues of amino acid sequence of protein YwfE, with the substitution being at least one of an asparagine (N) residue of the 108th place from the N terminal being substituted with at least one of an alanine (A) residue, a glutamic acid (E) residue and a glutamine (Q) residue, an isoleucine (I) residue of the 112th place from the N terminal being substituted with a valine (V) residue, and a histidine (H) residue of the 378th place from the N terminal being substituted with at least one of a lysine (K) residue or an arginine (R) residue.
Abstract: The invention relates to engineering of acetyl-CoA metabolism in yeast and in particular to production of acetyl-CoA in a non-ethanol producing yeast lacking endogenous gene(s) encoding pyruvate decarboxylase and comprising a heterologous pathway for synthesis of cytosolic acetyl-CoA.
Abstract: A genetically modified organism comprising: at least one nucleic acid sequence and/or at least one recombinant nucleic acid isolated from Alicyclobacillus acidocaldarius and encoding a polypeptide involved in at least partially degrading, cleaving, transporting, metabolizing, or removing polysaccharides, cellulose, lignocellulose, hemicellulose, lignin, starch, sugars, sugar oligomers, carbohydrates, complex carbohydrates, chitin, heteroxylans, glycosides, xylan-, glucan-, galactan-, or mannan-decorating groups; and at least one nucleic acid sequence and/or at least one recombinant nucleic acid encoding a polypeptide involved in fermenting sugar molecules to a product. Additionally, enzymatic and/or proteinaceous extracts may be isolated from one or more genetically modified organisms. The extracts are utilized to convert biomass into a product.
Type:
Grant
Filed:
July 15, 2019
Date of Patent:
June 23, 2020
Assignee:
Battelle Energy Alliance LLC
Inventors:
David N. Thompson, William A. Apel, Vicki S. Thompson, Thomas E. Ward
Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.
Type:
Grant
Filed:
September 3, 2019
Date of Patent:
June 23, 2020
Assignee:
The Regents of the University of California
Inventors:
Daniel Garrido, J. Bruce German, Carlito B. Lebrilla, David A. Mills